Translational Pharmacokinetic/Pharmacodynamic Modeling of Tumor Growth Inhibition Supports Dose-Range Selection of the Anti-PD-1 Antibody Pembrolizumab. - Wikidata - awgldk - TriplyDB

Translational Pharmacokinetic/Pharmacodynamic Modeling of Tumor Growth Inhibition Supports Dose-Range Selection of the Anti-PD-1 Antibody Pembrolizumab.

Translational Pharmacokinetic/Pharmacodynamic Modeling of Tumor Growth Inhibition Supports Dose-Range Selection of the Anti-PD-1 Antibody Pembrolizumab.

http://www.wikidata.org/entity/Q37609774

about

Population Pharmacokinetic/Pharmacodynamic Modeling of Tumor Size Dynamics in Pembrolizumab-Treated Advanced Melanoma.Commentary on Pharmacometrics for Immunotherapy.Pembrolizumab: Role of Modeling and Simulation in Bringing a Novel Immunotherapy to Patients With Melanoma.Immuno-oncology Clinical Trial Design: Limitations, Challenges, and Opportunities.From Famine to Feast: Developing Early-Phase Combination Immunotherapy Trials Wisely.Pembrolizumab in the treatment of advanced urothelial cancer.Immune checkpoint inhibitors in advanced non-small cell lung cancer.Evolution of early phase clinical trials in oncology.KEYNOTE-010: flash of a supernova (immune-checkpoint inhibitors) in second-line non-small cell lung cancer.Quantitative translational modeling to facilitate preclinical to clinical efficacy & toxicity translation in oncology.Tumor molecular profiling of responders and non-responders following pembrolizumab monotherapy in chemotherapy resistant advanced cervical cancer.Pharmacometric Applications and Challenges in the Development of Therapeutic Antibodies in Immuno-Oncology

P2860

Q37609777-7938448A-6D26-45B7-935F-EA66E9E80DF7 Q39082975-80C06F97-054D-4045-9A06-7C92F8F3AE17 Q42327769-F40F58ED-1771-408F-AC70-4768795D9960 Q45936626-3F79F4F5-B245-4182-9891-C111ECDBA832 Q45952214-B785A554-0AE3-47C7-9F56-AFB8C4C444DA Q47345366-030B86B4-8FB6-4236-9BB8-6276B19FF890 Q47563451-07BB22AE-CD91-4DDC-B364-208905A71057 Q47816379-A6D7C18C-7F7D-4B2F-B3D1-F6C8B100FA69 Q49217973-DA8C72F0-779C-43F8-A808-EFE00C9387E2 Q55329667-9A6B9954-9218-4986-93CC-92B7FC1D5809 Q55386599-19EF475A-148F-4BC3-9588-7A9D563E51DE Q57495826-5A524D6F-5C26-4B6F-AE06-140E21F89261

P2860

Translational Pharmacokinetic/Pharmacodynamic Modeling of Tumor Growth Inhibition Supports Dose-Range Selection of the Anti-PD-1 Antibody Pembrolizumab.

http://www.wikidata.org/entity/Q37609774

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年学术文章

@wuu

2016年学术文章

@zh-cn

2016年学术文章

@zh-hans

2016年学术文章

@zh-my

2016年学术文章

@zh-sg

2016年學術文章

@yue

2016年學術文章

@zh

2016年學術文章

@zh-hant

name

Translational Pharmacokinetic/ ...... i-PD-1 Antibody Pembrolizumab.

@en

Translational Pharmacokinetic/ ...... i-PD-1 Antibody Pembrolizumab.

@nl

type

label

Translational Pharmacokinetic/ ...... i-PD-1 Antibody Pembrolizumab.

@en

Translational Pharmacokinetic/ ...... i-PD-1 Antibody Pembrolizumab.

@nl

prefLabel

Translational Pharmacokinetic/ ...... i-PD-1 Antibody Pembrolizumab.

@en

Translational Pharmacokinetic/ ...... i-PD-1 Antibody Pembrolizumab.

@nl

P1433

Q37609774-F5CAEE33-1955-42F8-8270-8E46134B3D6A

P1476

Q37609774-8A5A0D9C-FD94-4F2E-9443-5AFFB22097AC

P2093

Q37609774-3105CB10-2BE2-41F0-9CF8-63BDF1BEE497

Q37609774-4BCCC6C9-2F93-4CEB-8764-7E9854AF38DD

Q37609774-53BAA1CB-3783-4303-82DC-F1D811205CC8

Q37609774-72261716-CDE7-4AE1-A1B1-558574FFDA36

Q37609774-B0E89B1F-B94E-4C34-90F3-AB8AA6930A33

Q37609774-D5DB0AA5-E0DC-4FFC-9347-D6E5ECC9DCF2

Q37609774-E8D905B9-AA5B-4B8B-B934-F4DCE6972A17

P2860

Q37609774-0624953D-0D79-4798-B16A-6A756D984685

Q37609774-14C0A601-6039-480D-848A-D22C40AA57D7

Q37609774-17454C8E-DAAA-463A-9EC1-05F8B787FEB6

Q37609774-2401062E-C394-4151-85BB-7E460F0B8717

Q37609774-385C36AA-2C9E-4B58-87E9-0C871F9226FA

Q37609774-3BAEFFFF-EFEB-4C67-9C01-7B886E8064D2

Q37609774-3D99491F-1278-461E-AA5C-FD2D5544BFAE

Q37609774-5404A12A-11A1-444A-8592-FD8841AC0315

Q37609774-5D33D5D9-22D4-4E21-A02D-C58D0C19D441

Q37609774-5FC60E3F-82E3-4BB3-81C6-71990F932AFC

P304

Q37609774-795353B5-5DFD-465C-8ED9-E05B61806E9C

P31

Q37609774-4C2939BF-4CCE-4BFB-BA15-CD3B58287776

P356

Q37609774-CAA62E7C-5F45-487E-A351-1DF968423B4F

P433

Q37609774-6E8322EC-0AE6-4AA6-AD8E-902C5F5F13E0

P478

Q37609774-56A9BABC-F7F2-4761-AEBE-1334BEB3C404

P577

Q37609774-91F19610-577F-4328-8F9C-5E244829501C

P698

Q37609774-EC4064F7-1DBA-4F9C-AA49-7950A5C376D1

P921

Q37609774-50CE7BE9-7D3A-4219-9C6E-54ADB3544F38

P932

Q37609774-94DA6C1B-9BDE-4A44-A86B-534350E51FD5

P356

P1433

CPT: pharmacometrics & systems pharmacology

P1476

Translational Pharmacokinetic/ ...... i-PD-1 Antibody Pembrolizumab.

@en

P2093

A Lindauer

http://www.w3.org/2001/XMLSchema#string

C R Valiathan

http://www.w3.org/2001/XMLSchema#string

D P de Alwis

http://www.w3.org/2001/XMLSchema#string

J Elassaiss-Schaap

http://www.w3.org/2001/XMLSchema#string

K Mehta

http://www.w3.org/2001/XMLSchema#string

R de Greef

http://www.w3.org/2001/XMLSchema#string

V Sriram

http://www.w3.org/2001/XMLSchema#string

P2860

Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma

The blockade of immune checkpoints in cancer immunotherapy

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

Tumor Immunotherapy Directed at PD-1

Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial

A review of mixed-effects models of tumor growth and effects of anticancer drug treatment used in population analysis.

Allometric scaling of metabolic rate from molecules and mitochondria to cells and mammals.

Immune regulation of cancer

Clinical applications of PD-1-based therapy: a focus on pembrolizumab (MK-3475) in the management of melanoma and other tumor types

P304

11-20

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/PSP4.12130

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

6

http://www.w3.org/2001/XMLSchema#string

P577

2016-11-08T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27863176

http://www.w3.org/2001/XMLSchema#string

P921

P932

5270293

http://www.w3.org/2001/XMLSchema#string